Guggenheim Forecasts Strong Price Appreciation for ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals (NASDAQ:ANIP) had its target price increased by stock analysts at Guggenheim from $119.00 to $121.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Guggenheim‘s price target suggests a potential upside of 79.50% from the stock’s current price.

Several other equities analysts also recently weighed in on ANIP. Leerink Partners assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, September 9th. They set an “outperform” rating and a $104.00 price target for the company. Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Canaccord Genuity Group decreased their price objective on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Finally, Oppenheimer began coverage on ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They set a “market perform” rating and a $85.00 price objective on the stock. Three equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $100.00.

ANI Pharmaceuticals Stock Down 3.2%

ANIP stock opened at $67.41 on Friday. The company’s 50 day simple moving average is $72.52 and its 200-day simple moving average is $77.32. The firm has a market capitalization of $1.55 billion, a PE ratio of 13.43, a P/E/G ratio of 2.17 and a beta of 0.45. ANI Pharmaceuticals has a 12 month low of $67.14 and a 12 month high of $95.45. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.75 and a quick ratio of 2.41.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Thursday, November 5th. The specialty pharmaceutical company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.18 by $0.52. ANI Pharmaceuticals had a return on equity of 28.34% and a net margin of 11.22%. The firm had revenue of $290.78 million during the quarter, compared to the consensus estimate of $280.59 million. During the same period in the previous year, the firm posted $2.04 EPS. The company’s quarterly revenue was up 27.6% compared to the same quarter last year. Equities analysts expect that ANI Pharmaceuticals will post 7.76 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Ori Gutwerg sold 3,162 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $77.00, for a total transaction of $243,474.00. Following the sale, the senior vice president owned 75,534 shares in the company, valued at approximately $5,816,118. This trade represents a 4.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Stephen P. Carey sold 2,850 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, October 29th. The stock was sold at an average price of $72.87, for a total transaction of $207,679.50. Following the completion of the sale, the chief financial officer directly owned 166,143 shares of the company’s stock, valued at $12,106,840.41. The trade was a 1.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 30,412 shares of company stock valued at $2,220,970. 8.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Aberdeen Group plc raised its stake in ANI Pharmaceuticals by 23.0% during the third quarter. Aberdeen Group plc now owns 334,350 shares of the specialty pharmaceutical company’s stock worth $24,291,000 after purchasing an additional 62,590 shares during the period. Eurizon Capital SGR S.p.A. acquired a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at $32,000. Maryland State Retirement & Pension System grew its stake in shares of ANI Pharmaceuticals by 66.4% during the 3rd quarter. Maryland State Retirement & Pension System now owns 4,430 shares of the specialty pharmaceutical company’s stock valued at $322,000 after buying an additional 1,768 shares during the period. Illinois Municipal Retirement Fund grew its stake in shares of ANI Pharmaceuticals by 7.2% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 9,719 shares of the specialty pharmaceutical company’s stock valued at $706,000 after buying an additional 651 shares during the period. Finally, Penn Capital Management Company LLC grew its stake in shares of ANI Pharmaceuticals by 2.8% during the 3rd quarter. Penn Capital Management Company LLC now owns 213,246 shares of the specialty pharmaceutical company’s stock valued at $15,515,000 after buying an additional 5,884 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Key Stories Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI reported Q3 2026 adjusted earnings of $2.70 per share, above the roughly $2.18 analyst consensus, and revenue of $290.78 million versus estimates of $280.59 million. Revenue grew 27.6% year over year, supporting the company’s growth outlook. ANI Q3 financial results
• Positive Sentiment: Guggenheim raised its price target from $119 to $121 and maintained a Buy rating, signaling continued analyst confidence in ANIP’s prospects. Guggenheim ratings
• Neutral Sentiment: ANI announced a recommended offer to acquire Swedish biotech Egetis Therapeutics for SEK 5.6 billion (about $560 million). The deal would expand ANI’s rare-disease business, but its financial impact and execution will matter to investors. ANI offer for Egetis
• Negative Sentiment: The sizable acquisition may raise concerns about funding, integration, and the risks of expanding into a new business, potentially weighing on shares despite the earnings beat. ANI offer to acquire Egetis

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.